Shots:
Blue Earth Diagnostics is advancing precision molecular imaging in prostate cancer through its F-18 PET imaging portfolio, with POSLUMA and Axumin designed to improve disease localization, support earlier clinical decision-making, and enhance physician confidence, particularly in patients experiencing biochemical recurrence.
At SNMMI 2026, the company presented new evidence highlighting POSLUMA's strong detection performance at low PSA levels, reduced urinary…
Shots:
PharmaShots' latest report chronicles the transformation of the global biopharma industry from 2006–2025, highlighting how innovation, strategic M&A, AI adoption, and evolving commercialization strategies have reshaped the competitive landscape while companies navigated patent cliffs, pricing pressures, and shifting market dynamics.
The report tracks the rise and fall of leading biopharma companies over two decades driven by…
The Evolution Summit returns September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA, bringing together leading clinical trial executives with innovative suppliers and solution providers in an invitation-only, premium setting.
Expect visionary keynotes, real-world case studies, and interactive forums aligned to the most pressing challenges in clinical operations and…
The Evolution Summit returns May 7-8, 2026 at The Ritz-Carlton, Fort Lauderdale, Florida, bringing together leading clinical trial executives with innovative suppliers and solution providers in an invitation-only, premium setting. Expect visionary keynotes, real-world case studies, and interactive forums aligned to the most pressing challenges in clinical operations and drug development. Featured leaders include…
Shots:
Thermo Fisher has entered into a definitive agreement to acquire Clario, enhancing its digital & data capabilities in clinical research
As per the deal, Thermo Fisher Scientific will acquire Clario for $8.875B in cash, with an additional $125M due in January 2027 & ~$400M in performance-based earnouts for 2026–2027; closing is expected mid-2026, after…
Shots:
Research into Lupus has yielded groundbreaking results in pharmacokinetics and pharmacodynamics, yet experts still don't understand its cause
Lupus Research Alliance (LRA) recently launched a platform called Data Repository, Exchange, and Analytics (DREAM) for data sharing and partnerships for research in lupus
Devon Kelly, Director of Lupus Nexus at the Lupus Research Alliance, sheds…
Shots:
Precision medicine holds a promising foothold in addressing unmet healthcare needs and bridging the gaps in care accessibility and high treatment costs
Defying the one-size-fits-all model, personalized medicine offers therapies tailored to an individual’s physiology, lifestyle, and environment
With this article, let’s capture the intricacies of precision medicine by navigating the benefits, challenges, progress,…
Shots:
AI is widely used in drug discovery and clinical research to find innovative cures for several debilitating conditions with unmet healthcare needs
Most of the AI architecture employs deep learning that requires extensive training data sets to produce reliable predictive models
Today, at PharmaShots, we have Adityo Prakash, CEO of Verseon, addressing the challenges…
Shots:
Marisa Cruz, MD, and Chief Medical Officer at Empatica, exchanged thoughts with PharmaShots on the revolutionary Empatica Health Monitoring Platform (EHMP)
Approved by the FDA in Nov’2022, EHMP leverages a cloud-based online portal to collect continuous and seamless physiological data from home and clinical setting
While conversing in great depth about Empatica’s EmbracePlus smartwatch,…
Shots:
Ahsan spoke about the US FDA acceptance for Priority Review of sBLAs for PADCEV and KEYTRUDA to treat patients with LA/mUC who are not eligible to receive cisplatin-containing CT
He also talked about the study design and outcomes from the P-Ib/II (EV-103) clinical trial that supported the sBLA. The results from Dose Escalation/Cohort A…

